World Courier Opens New Depot in Moscow
The new facility replaces the company’s current Moscow depot and increases its size and capabilities--including local sourcing of comparator drugs and secondary packaging and labeling.
World Courier, a global provider of specialty logistics and a part of AmerisourceBergen, will open a new investigational drug depot in Moscow, Russia, in August. The new facility replaces the company’s current Moscow depot and increases its size and capabilities. New services, include local sourcing of comparator drugs and secondary packaging and labeling, which allows for late-stage customization of products.
Moscow remains an area of interest for clinical trials, and of the 123 new drug therapies approved by CDER in 2015, 50 were studied in Russia. Experts say the number of clinical trials in Russia could double by 2020.
Read the full release.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
